CRYSTALLINE FORMS OF AFATINIB DI-MALEATE

• US 20150232457A1
• Filed: 04/25/2012
• Published: 08/20/2015
• Est. Priority Date: 10/06/2011
• Status: Abandoned Application

• Current Assignee: Ratiopharm GmbH (Teva Pharmaceutical Industries Limited)
• Original Assignee: Ratiopharm GmbH (Teva Pharmaceutical Industries Limited)
• Inventors: Eichner, Simone, Lehmann, Frank, Albrecht, Wolfgang, Bruns, Anja, Maier, Annemarie
• Application Number:
  US14/349,217
• Publication Number:
  US 20150232457A1
• Time in Patent Office: Days
• US Class Current: 1/1
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07D 405/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 407/12 linked by a chain containing hetero atoms as chain links

Abstract

Crystalline forms of Afatinib di-maleate are described in the present application and processes for their preparation. The present invention also includes pharmaceutical compositions of such crystalline forms of Afatinib di-maleate, methods of their preparation and the use thereof hi the treatment of a patient in need thereof. The present invention also describes preparing Afatinib free base and salts of Afatinib, other than Afatibin di-maleate, and solid forms thereof.

Claims

1-11. -11. (canceled)

12. Crystalline Afatinib di-maleate Form D, characterized by data selected from:

an X-ray powder diffraction pattern having peaks at 5.6, 9.5, 22.1, 26.3 and 29.5 degrees two theta±

0.2 degrees two theta;

an X-ray powder diffraction pattern substantially as depicted in FIG. 4; and

combinations thereof.

13. The crystalline Afatinib di-maleate Form D of claim 12, characterized by an X-ray powder diffraction pattern having peaks at 5.6, 9.5, 22.1, 26.3 and 29.5 degrees two theta±

0.2 degrees two theta.

14. The crystalline Afatinib di-maleate Form D of claim 13, further characterized by additional analytical data selected from:

an X-ray powder diffraction pattern having any one, two, three, four, five, six, seven, eight, nine or ten additional peaks selected from peaks at 11.2, 14.4, 18.5, 19.7, 20.5, 20.7, 22.3, 23.5, 24.8 and 28.1 degrees two theta±

0.2 degrees two theta;

a DSC thermogram substantially as depicted in FIG. 5; and

combinations thereof.

15. The crystalline Afatinib di-maleate Form D of claim 12, wherein said form is anhydrous.

17. A pharmaceutical composition comprising any one or a combination of Afatinib di-maleate crystalline forms according to claim 12 and at least one pharmaceutically acceptable excipient.

19. A method of treating cancer, comprising administering a therapeutically effective amount of at least one Afatinib di-maleate crystalline forms according to claim 12 to a person suffering from cancer.

20. A process for preparing Afatinib free base, or a salt of Afatinib other than a di-maleate salt, or any solid state form of said salt of Afatinib, the process comprising:

a) preparing a crystalline form of Afatinib di-maleate of claim 12;

b) basifying said form to obtain Afatinib free base; and

optionally

c) converting the obtained Afatinib free base to a salt of Afatinib other than a di-maleate salt, or a solid state form thereof.

21. The process of claim 20, wherein the conversion of step c) comprises:

reacting the obtained Afatinib free base with an appropriate acid to obtain the corresponding acid addition salt.

22. A process for preparing a salt of Afatinib other than a di-maleate salt, or any solid state form of said salt of Afatinib, the process comprising:

a) preparing a crystalline form of Afatinib di-maleate of claim 12; and

b) reacting said crystalline form with an acid having a pKa that is lower than of maleic acid to obtain the corresponding acid addition salt, or a solid state form thereof.

16. (canceled)

18. (canceled)